Status:
ACTIVE_NOT_RECRUITING
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Hidradenitis Suppurativa
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis suppurativa and to determine ...
Eligibility Criteria
Inclusion
- Patients with moderate to severe HS based on the number of lesions, fistulae and anatomical areas involved
- Minimal body weight of 50 kg
- Able to communicate well with the investigator and understand and comply with the requirements of the study, and the ability and willingness to conduct study visits as per the study schedule
Exclusion
- Use of other investigational drugs at the time of screening or before
- Women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception
- Pregnant or lactating women
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
February 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 11 2026
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT03827798
Start Date
February 27 2019
End Date
December 11 2026
Last Update
July 9 2025
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Olympian Clinical Research .
Clearwater, Florida, United States, 33756
2
Park Avenue Dermatology, PA
Orange Park, Florida, United States, 32073
3
University of South Florida
Tampa, Florida, United States, 33612
4
Advanced Medical Research
Sandy Springs, Georgia, United States, 30328